The Most Valuable KOLs in Your Network

Person Counting on Fingers

Rob Cross recently posted a clear insightful view about “The Most Valuable People in Your Network.” In regards to building social capital, he illustrates the difference between quality and quantity. I won’t repeat the article here, but it goes without saying that the same approach applies to Key Opinion Leaders.  At Lnx we often see… more »

Andrew Witty, CEO of GlaxoSmithKline: How to do more with less and still be innovative

GlaxoSmithKline CEO Andre Witty gives his view on what pharma must do to stay competitive in the future, but he leaves out useful information on innovating with few resources in a competitive environment.

Market Access is a Changing – Map Stakeholders to Understand Payor Policies

Writing an article about market forces and issues facing the Pharmaceutical industry is easy.  But Mark Halliday in his recent article “Success Factors for Market Access in the Pharmaceutical Industry” has put together a collection of ideas to to improve market access.  Mark talks about the need to recognize the market has fragmented, and then… more »

“Global Top 20” Shows US and UK Have the Most Influential Experts in Breast Cancer Research

Social Network Analysis of over 44,000 people by Lnx Pharma reveals key opinion leaders, power clusters and centers of excellence around the world in the research of breast neoplasms (breast cancer)

Twitter, Facebook, and Social Activism: NewYorker.com

PrarieDogs

Malcom Gladwell’s recent article “Twitter, Facebook, and Social Activism” in the New Yorker provides food for thought about the nature and value of weak social ties versus strong ties

Vicious Cycle or Virtuous Cycle? Thought Leaders Debate the Value of Thought Leaders

Spider web -Image# 7408

Where should we draw the line between considering pharmaceutical key opinion leaders as thought leaders vs. calling them “influence peddlers”? A recent article published in “The Chronicle of Higher Education” casts aspersions on the entire protocol of co-mingling powerful KOLs, medical doctors and the academic research community within the context of drug development. We disagree…

Proximity influences behavior and adoption rates

Social circles are either limiting or empowering, depending on who you ask

What’s better, more tightly clustered friends or more diverse friends in your social network? A recent article looks at behavioral adoption among social network models…

Report from KOL Relationship Summit

liberty_bell_1[1]

You couldn’t tell it was conference host eXL Pharma’s first year foray into a new subject area: KOL Relationship Summit. The dialogue amongst the audience and speakers was top notch – all too often, a conference is a series of talking heads, but that was not the case.

Supramapping the avian flu? The next big social network?

3842023327_59b043661e[1]

What is a  “Supramap?”  It seems the world of network analysis is exploding, coming up with new terms nearly as rapidly as this article on the spread of H5N1 avian flu virus: “Supramapping Upcoming Pathogenic Storms” examines the research done by Daniel Janies, associate professor of biomedical informatics at Ohio State and senior author of… more »

Nicholas Christakis: The hidden influence of social networks

Putting a Face on the Crowd

Christakis speaks powerfully on the value of social networks. Beyond the shear elegance and compelling delivery, his thoughts have something for everyone.   He eloquently educates  the  audience on the fundamentals of social networks.  But then piles it on to provide stunning implications. Christakis provides a clear way to look at things differently.  For example, the… more »